1 / 11

Glecaprevir - Pibrentasvir in GT 1- 6 with Renal Disease EXPEDITION-4

Phase 3. Renal Disease. Treatment-Naïve and Treatment-Experienced. Glecaprevir - Pibrentasvir in GT 1- 6 with Renal Disease EXPEDITION-4. Source: Gane E, et al . N Engl J Med. 2017;377:1448-55. Glecaprevir - Pibrentasvir in Genotype 1-6 with Renal Disease EXPEDITION-4: Study Features.

triveni
Download Presentation

Glecaprevir - Pibrentasvir in GT 1- 6 with Renal Disease EXPEDITION-4

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 Renal Disease Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in GT 1-6 with Renal DiseaseEXPEDITION-4 Source: GaneE, et al. N Engl J Med. 2017;377:1448-55.

  2. Glecaprevir-Pibrentasvirin Genotype 1-6 with Renal DiseaseEXPEDITION-4: Study Features Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

  3. Glecaprevir-Pibrentasvirin Genotype 1-6 with Renal DiseaseEXPEDITION-4: Treatment Regimen 0 12 24 Week GT 1-6 CKD stage 4-5 Glecaprevir-Pibrentasvir(n = 104) SVR12 Abbreviations: CKD = chronic kidney diseaseDrug Dosing: Glecaprevir-pibrentasvir (100/40 mg) fixed dose combination; three pills once daily Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

  4. Glecaprevir-Pibrentasvirin Genotype 1-6 with Renal DiseaseEXPEDITION-4: Baseline Characteristics Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

  5. Glecaprevir-Pibrentasvirin Genotype 1-6 with Renal DiseaseEXPEDITION-4: Baseline Characteristics Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

  6. Glecaprevir-Pibrentasvirin Genotype 1-6 with Renal DiseaseEXPEDITION-4: Baseline Characteristics (Renal) Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

  7. Glecaprevir-Pibrentasvirin Genotype 1-6 with Renal DiseaseEXPEDITION-4: Results Sustained Virologic Response Rates (SVR) 103/104 102/104 100/104 Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

  8. Glecaprevir-Pibrentasvirin Genotype 1-6 with Renal DiseaseEXPEDITION-4: Results Sustained Virologic Response Rates (SVR) 1 died (2 wks post-tx); 1 stopped Rx @ week 4 2 patients lost to follow-up between post-treatment week 12 and 24 103/104 102/104 100/104 Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

  9. Glecaprevir-Pibrentasvirin Genotype 1-6 with Renal DiseaseEXPEDITION-4: Adverse Events Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

  10. Glecaprevir-Pibrentasvir in Genotype 1-6 with Renal DiseaseEXPEDITION-4: Adverse Events Conclusions Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

  11. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related